The efficacy of cabozantinib in lung cancer

Cabozantinib is a multi-target tyrosine kinase inhibitor that was first used to treat advanced renal cell carcinoma (RCC) and medullary thyroid cancer. In recent years, it has shown potential value in the study of lung cancer, especially non-small cell lung cancer (NSCLC) and its metastatic types. Its main mechanism of action includes inhibiting signaling pathways such as MET, VEGFR, and AXL, thereby interfering with the proliferation, angiogenesis, and migration of tumor cells. This characteristic allows cabozantinib to exert an anti-tumor effect in lung cancer patients and delay disease progression.

Clinical research and multiple overseas trial data show that cabozantinib has shown certain efficacy in the late-line treatment ofALK-positive or ROS1-positive non-small cell lung cancer. Its mechanism of action not only involves directly inhibiting tumor proliferation, but also inhibits angiogenesis and reduces tumor blood supply by regulating the tumor microenvironment. Especially for patients who are resistant to traditional chemotherapy or other targeted drugs, cabozantinib can be an effective option and provide patients with a new treatment approach. The multi-target inhibitory properties mean that it has advantages in inhibiting drug resistance-related signaling pathways and can delay the progression of tumor resistance to single-target drugs.

Another key feature of cabozantinib in the treatment of lung cancer is its potential control of bone metastases and liver metastases. Overseas clinical data show that after receiving cabozantinib treatment, some patients experienced pain relief in bone metastases, stable or reduced imaging lesions, and improved quality of life. In addition, cabozantinib is also being studied in patients with advanced lung cancer and brain metastases. Because it can cross the blood-brain barrier to a certain extent, it provides new treatment possibilities for central nervous system metastases.

Although cabozantinib has certain advantages in efficacy, adverse reactions still need to be closely monitored during its use, including hypertension, fatigue, rash, diarrhea, and hematological abnormalities. In clinical practice, doctors will adjust the dosage according to patient tolerance to balance efficacy and safety.

Reference:https://en.wikipedia.org/wiki/Cabozantinib